Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

The First Affiliated Hospital with Nanjing Medical University: Clinical Trials & FDA Approval Profile

The First Affiliated Hospital with Nanjing Medical University (Global / Institutional) sponsors 170 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 102 active protocols (60 recruiting now), 11 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)1.2%
Median Closed Enrollment vs National (145 pts)41 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for The First Affiliated Hospital with Nanjing Medical University
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)170
Active Pipeline (Recruiting Now)102 (60)
Completed vs Stopped Early11 / 2 (1.2%)
Median Closed Actual Enrollment41 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With The First Affiliated Hospital with Nanjing Medical University
Hospital Research SiteLocationShared Protocols
Jiangsu Province HospitalNanjing, Jiangsu22
Xuzhou central HospitalXuzhou, Jiangsu3

Explore interactive annual charts and M&A subsidiary rollups in the The First Affiliated Hospital with Nanjing Medical University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI